Last reviewed · How we verify
Angimuth (bismuth camphocarbonate)
Angimuth (generic name: bismuth camphocarbonate) is a drug. It is currently in unknown development.
Angimuth works by interacting with specific biological pathways to produce its therapeutic effect.
Angimuth is a small molecule that activates coagulation factor XII. It is classified as a basic bismuth gallate, a type of activator.
At a glance
| Generic name | bismuth camphocarbonate |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like a complex machine with many moving parts. Angimuth is a small tool that fits into a specific part of the machine, helping to fix a problem or make the machine work better. However, the exact way it fits into the machine and how it helps is not yet fully understood.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angimuth CI brief — competitive landscape report
- Angimuth updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Angimuth
What is Angimuth?
How does Angimuth work?
What is the generic name of Angimuth?
What development phase is Angimuth in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing